More than 1,600 subjects enrolled in PROTECT study Topline data expected mid-2019 VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”) today announced the completion of enrollment with the last patient receiving the first dose in the ongoing PROTECT Phase 3 study of...
Read More
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modification Low-dose study arm: enrollment complete Intermediate-dose study arm: enrollment commenced VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology...
Read More
VBI Vaccines Inc. ("VBI" or the "Company") (Nasdaq: VBIV) (TSX:VBV), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has applied to voluntarily delist its common shares (the "Shares") from the Toronto Stock Exchange...
Read More
Sam Chawla, of Perceptive Advisors, to resign from VBI Board of Directors Tomer Kariv, Chairman and CEO of The Pontifax Group, to replace Ran Nussbaum on VBI’s Board of Directors VBI Vaccines Inc. (Nasdaq: VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical...
Read More
Two-part Phase 1/2a study of VBI-1901 to enroll patients with recurrent GBM Part A: Dose escalation to enroll up to 18 patients Part B: Subsequent extension of optimal dose to enroll up to 10 additional patients VBI Vaccines Inc. (Nasdaq:VBIV)...
Read More
Patient dosing commenced on December 18, 2017 4,800 subjects across two Phase 3 studies: PROTECT and CONSTANT 15-month program - headline data expected Q2 2019 VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) announced today the initiation of the global...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX:VBV) (VBI) today announced that Jeff Baxter, President and CEO, will present at the BMO Capital Markets Prescriptions for Success Healthcare Conference on Thursday, December 14, 2017, at 11:00 AM ET in New York. The...
Read More
New data confirms use of intradermal delivery of eVLPs may be a potent “off-the-shelf” immunotherapy vaccine Poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 32nd Annual Meeting on Friday, November 10th VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV)...
Read More
Ran Nussbaum, managing partner and co-founder of The Pontifax Group, joins VBI Board of Directors Pontifax’s participation in the recent financing was alongside investments from several new fundamental life sciences institutional funds and insiders, notably Perceptive Advisors This financing provides...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the closing of its previously announced underwritten public offering of 16,100,000 common shares, which included 2,100,000 shares sold pursuant...
Read More